Compare FTHM & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHM | MYO |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 33.2M |
| IPO Year | 2020 | 2017 |
| Metric | FTHM | MYO |
|---|---|---|
| Price | $1.29 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $7.67 |
| AVG Volume (30 Days) | 195.5K | ★ 801.8K |
| Earning Date | 11-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $421,612,000.00 | $41,643,203.00 |
| Revenue This Year | $25.22 | $24.69 |
| Revenue Next Year | $16.19 | $20.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 32.78 | ★ 65.00 |
| 52 Week Low | $0.65 | $0.71 |
| 52 Week High | $3.37 | $7.17 |
| Indicator | FTHM | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 52.08 |
| Support Level | $1.18 | $0.71 |
| Resistance Level | $1.33 | $0.88 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 51.83 | 69.00 |
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).